Rachel Grisham
Memorial Sloan Kettering Cancer Center · GOG Foundation
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Rachel Grisham as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:45 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06394804 · A Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian CancerMemorial Sloan Kettering Cancer Center · recruiting · Low-Grade Serous Ovarian Cancer · principal investigator
- Ph2NCT06240598 · A Study of Second Look Laparoscopy (SLL) in People With Ovarian Cancer Who Have Completed Their First Course of ChemotherapyMemorial Sloan Kettering Cancer Center · active not recruiting · Ovarian Cancer · principal investigator
- Ph3NCT06072781 · A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian CancerVerastem, Inc. · recruiting · Low Grade Serous Ovarian Cancer · principal investigator
- Ph2NCT05787561 · A Study of Avutometinib (VS-6766) and Defactinib in People With Mesonephric Gynecologic CancerMemorial Sloan Kettering Cancer Center · active not recruiting · Mesonephric Gynecologic Cancer · principal investigator
- Ph2NCT04625270 · A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS MutationVerastem, Inc. · active not recruiting · Low Grade Ovarian Serous Adenocarcinoma, Ovarian Cancer · principal investigator
- Ph2NCT03909152 · A Study of Onapristone ER Alone Or In Combination With Anastrozole in Gynecologic Cancers That Respond to ProgesteroneMemorial Sloan Kettering Cancer Center · completed · Granulosa Cell Ovarian Cancer, Low Grade Serous Ovarian/ Primary Peritoneal Cancer, Endometrioid Endometrial Cancer · principal investigator
- Ph2NCT01974765 · Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior TherapiesMemorial Sloan Kettering Cancer Center · completed · Advanced Epithelial Ovarian, Recurrent Epithelial Ovarian, Fallopian Tube · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:45 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:45 UTC. The ranking covers the 200 most relevant of 25 PubMed records, and a shared surname and initials can bring in a namesake. All 25 on PubMed
- 133 citationsRCR 5.1
- Secondary Cytoreduction and Carboplatin Hyperthermic Intraperitoneal Chemotherapy for Platinum-Sensitive Recurrent Ovarian Cancer: An MSK Team Ovary Phase II Study.J Clin Oncol · 2021111 citationsRCR 6.9
- Bevacizumab shows activity in patients with low-grade serous ovarian and primary peritoneal cancer.Int J Gynecol Cancer · 201478 citationsRCR 2.3
- Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201.J Clin Oncol · 202559 citationsRCR 12.6
- 57 citationsRCR 2.4
- Safety, immunogenicity, and clinical efficacy of durvalumab in combination with folate receptor alpha vaccine TPIV200 in patients with advanced ovarian cancer: a phase II trial.J Immunother Cancer · 202050 citationsRCR 1.9
- Relacorilant + Nab-Paclitaxel in Patients With Recurrent, Platinum-Resistant Ovarian Cancer: A Three-Arm, Randomized, Controlled, Open-Label Phase II Study.J Clin Oncol · 202344 citationsRCR 3.4
- Phase Ib Study of Binimetinib with Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer: Final Results, Potential Biomarkers, and Extreme Responders.Clin Cancer Res · 201827 citationsRCR 0.8
- Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: a phase 2 trial with biomarker analyses.Nat Med · 202427 citationsRCR 2.4
- Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer.Clin Cancer Res · 202324 citationsRCR 1.6